ASRT - デポメッド (Assertio Therapeutics Inc.) デポメッド

 ASRTのチャート


 ASRTの企業情報

symbol ASRT
会社名 Assertio Therapeutics Inc (デポメッド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 デポメッド(Depomed Inc)専門製薬会社である。同社は疼痛および他の中枢神経系(CNS)疾患を主要治療対象とする。同社の製品はNUCYNTA ER(タペンタドール延長放出錠剤)、NUCYNTA IR (NUCYNTA)(タペンタドール)、Gralise(ガバペンチン)、CAMBIA(経口溶液用ジクロフェナクカリウム)、Zipsor(ジクロフェナクカリウム)、及びLazanda(フェンタニル)を含む。同社のNUCYNTA ER(タペンタドール延長放出錠剤)は成人における糖尿病性末梢神経障害に関連する神経因性疼痛を含む毎日の長期オピオイド治療が必要な疼痛管理製品で、NUCYNTA IR(タペンタドール)は大人の重度の急性痛に対する製品である。同社のGralise(ガバペンチン)はヘルペス後神経痛の1日1回製品である。CAMBIA(経口溶液用ジクロフェナクカリウム)は片頭痛発作の急性の治療のための製品である。   デポメッドは、痛みや中枢神経系疾患に焦点を当てた米国の製薬会社。主要薬品は、帯状疱疹後神経痛薬Gralise(ガバペンチン)急性の痛みを軽減する液体充填カプセルZipsor(ジクロフェナクカリウム)、成人のがん患者向け痛み止め薬鼻スプレ―Lazanda(フェンタニル)、偏頭痛薬CAMBIA(ジクロフェナクカリウム経口溶液)などを含む。   
本社所在地 7999 Gateway Boulevard Suite 300 Newark CA 94560 USA
代表者氏名
代表者役職名
電話番号 +1 224-419-7106
設立年月日 34912
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 434人
url www.depomed.com
nasdaq_url https://www.nasdaq.com/symbol/asrt
adr_tso
EBITDA EBITDA(百万ドル) 171.81900
終値(lastsale) 5.79
時価総額(marketcap) 370072285.14
時価総額 時価総額(百万ドル) 361.76320
売上高 売上高(百万ドル) 381.49800
企業価値(EV) 企業価値(EV)(百万ドル) 884.56820
当期純利益 当期純利益(百万ドル) -10.82000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Assertio Therapeutics Inc revenues increased less than 1% to $191.7M. Net income totaled $12.8M vs. loss of $53.4M. Revenues reflect Royalties and milestones increase from $387K to $5.5M also reflect Product Sales decrease of 63% to $71.2M. Net income reflects Selling general and administrative expe decrease of 40% to $55.5M (expense).

 ASRTのテクニカル分析


 ASRTのニュース

   The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs  2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
   Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering | MarketScreener  2021/02/10 05:01:02 MarketScreener
LAKE FOREST, Ill., Feb. 10, 2021 -- Assertio Holdings, Inc. today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 35,000,000… | February 10, 2021
   Assertio Seeks To Raise $14M Via Equity At 21% Discount From Thursday's Close  2021/02/05 07:04:00 Benzinga
Assertio Holdings Inc (NASDAQ: ASRT) has entered into a securities purchase agreement with certain institutional investors to purchase …
   Assertio Holdings, Inc. Announces Pricing of $14 Million Registered Direct Offering | MarketScreener  2021/02/05 05:05:00 MarketScreener
LAKE FOREST, Ill., Feb. 05, 2021 -- Assertio Holdings, Inc. today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 22,600,000… | February 5, 2021
   Diabetic Neuropathy Market 2020 to Witness High Growth in Near Future | Top Key Players like BoehringerIngelheim, Arbor Pharmaceuticals, Depomed  2020/11/10 10:03:32 OpenPR
“Diabetic Neuropathy Market is expected to grow at a CAGR of +8% during forecast period 2020- 2026.” " Diabetic Neuropathy " is the harm caused to the nerve because of diabetes which frequently prompts torment and deadness in feet or lower
   The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs  2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
   Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering | MarketScreener  2021/02/10 05:01:02 MarketScreener
LAKE FOREST, Ill., Feb. 10, 2021 -- Assertio Holdings, Inc. today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 35,000,000… | February 10, 2021
   Assertio Seeks To Raise $14M Via Equity At 21% Discount From Thursday's Close  2021/02/05 07:04:00 Benzinga
Assertio Holdings Inc (NASDAQ: ASRT) has entered into a securities purchase agreement with certain institutional investors to purchase …
   Assertio Holdings, Inc. Announces Pricing of $14 Million Registered Direct Offering | MarketScreener  2021/02/05 05:05:00 MarketScreener
LAKE FOREST, Ill., Feb. 05, 2021 -- Assertio Holdings, Inc. today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 22,600,000… | February 5, 2021
   Diabetic Neuropathy Market 2020 to Witness High Growth in Near Future | Top Key Players like BoehringerIngelheim, Arbor Pharmaceuticals, Depomed  2020/11/10 10:03:32 OpenPR
“Diabetic Neuropathy Market is expected to grow at a CAGR of +8% during forecast period 2020- 2026.” " Diabetic Neuropathy " is the harm caused to the nerve because of diabetes which frequently prompts torment and deadness in feet or lower
   The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs  2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
   Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering | MarketScreener  2021/02/10 05:01:02 MarketScreener
LAKE FOREST, Ill., Feb. 10, 2021 -- Assertio Holdings, Inc. today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 35,000,000… | February 10, 2021
   Assertio Seeks To Raise $14M Via Equity At 21% Discount From Thursday's Close  2021/02/05 07:04:00 Benzinga
Assertio Holdings Inc (NASDAQ: ASRT) has entered into a securities purchase agreement with certain institutional investors to purchase …
   Assertio Holdings, Inc. Announces Pricing of $14 Million Registered Direct Offering | MarketScreener  2021/02/05 05:05:00 MarketScreener
LAKE FOREST, Ill., Feb. 05, 2021 -- Assertio Holdings, Inc. today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 22,600,000… | February 5, 2021
   Diabetic Neuropathy Market 2020 to Witness High Growth in Near Future | Top Key Players like BoehringerIngelheim, Arbor Pharmaceuticals, Depomed  2020/11/10 10:03:32 OpenPR
“Diabetic Neuropathy Market is expected to grow at a CAGR of +8% during forecast period 2020- 2026.” " Diabetic Neuropathy " is the harm caused to the nerve because of diabetes which frequently prompts torment and deadness in feet or lower

 関連キーワード  (医薬品 米国株 デポメッド ASRT Assertio Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)